The role of abuse-deterrent formulations in countering opioid misuse and abuse

被引:9
作者
Nguyen, V. [1 ]
Raffa, R. B. [1 ]
Taylor, R. [2 ]
Pergolizzi, J. V., Jr. [3 ,4 ,5 ]
机构
[1] Temple Univ, Sch Pharm, Philadelphia, PA 19122 USA
[2] NEMA Res, Bonita Springs, FL USA
[3] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA
[4] Temple Univ, Dept Pharmacol, Sch Med, Philadelphia, PA 19122 USA
[5] Assoc Chron Pain Patients, Houston, TX USA
关键词
abuse; abuse-deterrent formulation; opioids; pain management; HYDROCHLORIDE; RESISTANT; CROSSOVER; THERAPY; TABLETS; ROUTES; IMPACT; SAFETY; SAMPLE; RISKS;
D O I
10.1111/jcpt.12337
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
What is known and objective: Pain is a prevalent, and due to the ageing population, increasing medical problem. Opioids are frequently prescribed to meet the unmet medical need. Unfortunately, with the increase in the legitimate use of opioids, there has been a corresponding increase in abuse. A practical way to retain the pain relief afforded by opioids while decreasing opportunities for abuse is to make it more difficult to extract the opioid from the product or to make it less desirable to do so by designing an abuse-deterrent formulation ( ADF). We provide a brief overview of the strategies and early evidence related to opioid ADFs. Methods: Published and unpublished literature, websites, and other sources were searched for current opioid formulation options, including immediate-release and extended-release products. Each was summarized, reviewed and assessed. Results: The strategies that have been used to design the current opioid ADFs involve one or more of four approaches: a physical barrier; incorporation of an opioid receptor antagonist (e.g. naloxone) that self-limits opioid action when taken in excess amount; inclusion of a noxious agent that is released during inappropriate use; or a pro-drug. What is new and conclusions: Legitimate use of opioid analgesics carries with it certain risks, including the risk of abuse. The new ADFs utilize four major strategies and provide innovative additions to the armamentarium. They likely will become an important part of a comprehensive approach to limiting, although not eliminating, opioid misuse and abuse.
引用
收藏
页码:629 / 634
页数:6
相关论文
共 20 条
[1]   Development and impact of prescription opioid abuse deterrent formulation technologies [J].
Alexander, Louis ;
Mannion, Richard O. ;
Weingarten, Brianne ;
Fanelli, Richard J. ;
Stiles, Gary L. .
DRUG AND ALCOHOL DEPENDENCE, 2014, 138 :1-6
[2]  
[Anonymous], J PAIN S1
[3]  
Black Ryan A, 2013, J Opioid Manag, V9, P5, DOI 10.5055/jom.2013.0142
[4]   Abuse Rates and Routes of Administration of Reformulated Extended-Release Oxycodone: Initial Findings From a Sentinel Surveillance Sample of Individuals Assessed for Substance Abuse Treatment [J].
Butler, Stephen F. ;
Cassidy, Theresa A. ;
Chilcoat, Howard ;
Black, Ryan A. ;
Landau, Craig ;
Budman, Simon H. ;
Coplan, Paul M. .
JOURNAL OF PAIN, 2013, 14 (04) :351-358
[5]   Abuse risks and routes of administration of different prescription opioid compounds and formulations [J].
Butler, Stephen F. ;
Black, Ryan A. ;
Cassidy, Theresa A. ;
Dailey, Taryn M. ;
Budman, Simon H. .
HARM REDUCTION JOURNAL, 2011, 8
[6]   The Effectiveness and Risks of Long-Term Opioid Therapy for Chronic Pain: A Systematic Review for a National Institutes of Health Pathways to Prevention Workshop [J].
Chou, Roger ;
Turner, Judith A. ;
Devine, Emily B. ;
Hansen, Ryan N. ;
Sullivan, Sean D. ;
Blazina, Ian ;
Dana, Tracy ;
Bougatsos, Christina ;
Deyo, Richard A. .
ANNALS OF INTERNAL MEDICINE, 2015, 162 (04) :276-+
[7]   2009 Clinical Guidelines from the American Pain Society and the American Academy of Pain Medicine on the use of chronic opioid therapy in chronic noncancer pain What are the key messages for clinical practice? [J].
Chou, Roger .
POLSKIE ARCHIWUM MEDYCYNY WEWNETRZNEJ-POLISH ARCHIVES OF INTERNAL MEDICINE, 2009, 119 (7-8) :469-476
[8]   Abuse liability of prescription opioids compared to heroin in morphine-maintained heroin abusers [J].
Comer, Sandra D. ;
Sullivan, Maria A. ;
Whittington, Robert A. ;
Vosburg, Suzanne K. ;
Kowalczyk, William J. .
NEUROPSYCHOPHARMACOLOGY, 2008, 33 (05) :1179-1191
[9]   An iterative model for in vitro laboratory assessment of tamper deterrent formulations [J].
Cone, Edward J. ;
Giordano, Jennifer ;
Weingarten, Brianne .
DRUG AND ALCOHOL DEPENDENCE, 2013, 131 (1-2) :100-105
[10]  
FDA, GUID IND AB DET OP E